Sequence: RRRRRRRR
| Experiment Id | EXP000787 |
|---|---|
| Paper | Polyethylene glycol and octaarginine dual-functionalized nano-graphene oxide: An optimization for ef |
| Peptide | Octaarginine (R8) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 100 ng (FITC-siRNA used in uptake/localization); si-c-Myc amount not explicitly stated |
| Mixing Ratio | N/P=10 |
| Formulation Format | Graphene oxide (GO) nanosheet nanocarrier (dual-functionalized) |
| Formulation Components | Carboxylated nano-graphene oxide (GO) covalently co-conjugated with PEG-diamine and octaarginine (R8); optimized formulation GPPo (GPP3, PEG:R8=10:1) |
| Size Nm | 252.00 |
| Zeta Mv | 40.97 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB 231 (breast cancer) |
| Animal Model | |
| Administration Route | |
| Output Type | Protein knockdown (western blot) |
| Output Value | c-Myc downregulated vs non-treated; lower knockdown than HiPerFect |
| Output Units | |
| Output Notes | siRNA/GPPo complexes at N/P=10; uptake ~85±3.4% relative to HiPerFect; knockdown assessed 72 h post-transfection |
| Toxicity Notes | GPPo showed no cytotoxicity below 250 µg/mL in MDA-MB 231 after 48 h; 150 µg/mL used for transfection |
| Curation Notes |